Graham, I. and Robinson, K. and Tomkin, G. and Bradford, N.C. and Wilkinson, P. and Buckley, B. and Seed, M. and Marenah, C.B. and Silas, J. and Caplice, N. and Fennell, W. and Went, J. and Repper, J. and Vannan, M. and Taylor, C. and Richardson, P.J. and Grant, A. and Counihan, T.B. and Hersh, A.D. and Guptha, S. and Gentry, R. and Young, J. and Gwilt, D.J and Fox, K. and Mulcahy, C. and Greenwood, R.H. and Rowlands, D.B. and Cramb, R. and Mourant, A.J. and Taylor, W.H. and Walker, B.A. and Allen, S.G. and Wood, D.A. and Iversen, S.A. and Laker, M.F. and Gama, R.M. and Hughes, E.A. and Polanska, A. and Bennett, E.D. and Wray, R. and Ginks, S. and Crean, P.A. and Hall, M. and Hartley, P. and O'Connor, P. and Walsh, M. and Baynes, C. and Elkeles, R.S. and Bloomfield, P. and Wright, R. and Lindsey, J. and Cullen, P. and Mi, M.A. and Feely, J. and Lockton, A. and Fink, R.S. and Wilson, I. and Miller, J.P. and Davies, R. and Patterson, D.L.H. and Bruce, R. and Crook, C. and Wynn, V. and Oliver, M. (1994) A one -Year Multicenter Study of Simvastatin in the Treatment of Hypercholesterolemia. British Journal of Clinical Practice, 48 (5). pp. 231-235. ISSN 0007-0947. (The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided)
A 1-year prospective study was conducted in 475 hypercholesterolaemic men and women who received simvastatin monotherapy 10-40 mg daily for 3 months followed by additional lipid-lowering medication after this period, if necessary, to reach a target of plasma cholesterol <5.3 mmol/l. Of these, 403 subjects completed 1 year of follow-up. By the end of the 3-month monotherapy period, the following percentage mean changes were seen (with 95% confidence intervals): total cholesterol (TC) -31% (-30 to -32%), low-density lipoprotein cholesterol -39% (-38 to -40%), triglycerides -14% (-11 to -17%) and high-density lipoprotein cholesterol +12% (+11 to +14%). These levels were maintained for the remainder of the study. When subjects with a baseline TC of 6.5-7.8 mmol/l were considered (n=89), 42.7% achieved the target TC levels on simvastatin monotherapy alone. Additional hypolipidaemic medication had no Significant impact on plasma lipid and lipoprotein levels. Simvastatin was well tolerated both as monotherapy and in combination.
|Subjects:||R Medicine > R Medicine (General)|
|Divisions:||Faculties > Science Technology and Medical Studies > Kent Institute of Medicine and Health Sciences (KIMHS)|
|Depositing User:||P. Ogbuji|
|Date Deposited:||26 Jun 2009 15:36|
|Last Modified:||20 Feb 2015 09:11|
|Resource URI:||https://kar.kent.ac.uk/id/eprint/20221 (The current URI for this page, for reference purposes)|